imtox-25
mAbexperimentalADC
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2001 (NCT00025662)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Graft vs Host Disease · Phase 2
- Hodgkin Disease · Phase 2
- Leukemia · Phase 2
- Leukemia, Lymphoid · Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 2
- Leukemia, Myeloid · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Phase 2
- Melanoma · Phase 2
- Myelodysplastic Syndromes · Phase 2
Mechanism of action
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Ricin A chain
Oral
No
Parenteral
No
Topical
No
Also known as
- imtox-25
- rft5-dga immunotoxin
- rft5-smpt-dga
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01378871 | Phase 2 | Sep 1, 2010 | Yeshiva University |
| NCT00667017 | Phase 2 | Jul 1, 2008 | The University of Texas, Dallas |
| NCT00314093 | Phase 2 | Apr 1, 2006 | National Cancer Institute (NCI), The University of Texas, Dallas |
| NCT00025662 | Phase 2 | May 1, 2001 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| The University of Texas, Dallas | Academic/Hospital | 2 | 2 | 1 | 2006 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2006 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 2001 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2001 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2010 |
5 organizations
Page 1 / 1